- Home>
- Search Results
Search Results
Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.
Sort by:
Items 1 to 20 of 341 results - Relevance
- Date
You searched for: new antiretroviral drugs in HIV/AIDS
-
Causes of Death Among AIDS Patients in New York City, 1999–2004
- October 2, 2006
- Carlos del Rio, MD
- HIV/AIDS
More than one fourth of AIDS patients in NYC now die from non–HIV-related causes.- Reviewing:
- Sackoff JE et al., Ann Intern Med 2006 Sep 19; 145:397-406. Aberg JA., Ann Intern Med 2006 Sep 19; 145:463-5.
-
New Guidelines for Antiretroviral Therapy in Nonoccupational Postexposure Prophylaxis
- March 1, 2005
- Carlos del Rio, MD
- HIV/AIDS
In late January, the CDC released guidelines on the use of antiretroviral therapy in individuals possibly exposed to HIV through sexual intercourse, injection-drug use, or . . .- Reviewing:
- , MMWR Recomm Rep 2005 Jan 21; 54:1-20.
-
New Classes, New Agents: Changing the Paradigm of Antiretroviral Treatment? Free
- April 2, 2007
- Judith Feinberg, MD
- HIV/AIDS
Raltegravir (the first integrase inhibitor) and maraviroc (the first CCR5 inhibitor) are both effective and well tolerated in highly treatment-experienced patients. -
The New York “Superstrain” of HIV: From Panic to Understanding
- December 28, 2005
- HIV/AIDS
The rapid progression of infection in the now-famous New York case was most likely due to host factors rather than a highly virulent strain of HIV. -
Old Drugs, New Data
- September 14, 2005
- Charles B. Hicks, MD
- HIV/AIDS
Researchers at IAS reported on the benefits of once-daily tenofovir + FTC + efavirenz as initial therapy, described a new needle-free injection system for T-20, and announced the impending availability of lopinavir/ritonavir in tablet formulation. -
Antiretroviral Drug Resistance Testing — Updated Guidelines from the IAS–USA
- July 14, 2008
- Charles B. Hicks, MD
- HIV/AIDS
The latest guidelines include updated information on resistance to both old and new drugs and provide specific recommendations for the clinical application of resistance testing.- Reviewing:
- Hirsch MS et al., Clin Infect Dis 2008 Jul 15; 47:266.
-
Durability of Initial Antiretroviral Regimens in the Swiss HIV Cohort
- June 30, 2008
- Charles B. Hicks, MD
- HIV/AIDS
ART success rates have improved over time — currently, more than 90% of patients achieve viral suppression at 1 year — but switching because of intolerance remains common.- Reviewing:
- Vo TTN et al., J Infect Dis 2008 Jun 15; 197:1685.
-
Another Stab at Defining the Best Antiretroviral Combination
- September 1, 2006
- Abigail Zuger, MD
- HIV/AIDS
A retrospective review suggests that many of the most common regimens perform indistinguishably.- Reviewing:
- The Antiretroviral Therapy Cohort Collaboration., J Infect Dis 2006 Sep 1; 194:612-22.
-
Generic Antiretroviral Therapy Works Well in Haiti
- January 18, 2006
- Keith Henry, MD
- HIV/AIDS
Treatment-naive patients receiving generic NNRTI-based potent combination antiretroviral therapy in Haiti have had positive results similar to those seen in the U.S.- Reviewing:
- Severe P et al., N Engl J Med 2005 Dec 1; 353:2325-34. Kim JY and Gilks C., N Engl J Med 2005 Dec 1; 353:2392-4.
-
Strategies for Antiretroviral Deintensification
- August 31, 2009
- Charles B. Hicks, MD
- HIV/AIDS
Data presented at IAS 2009 highlighted new approaches to PI therapy for patients with virologic suppression, including simplifying ritonavir-boosted atazanavir to unboosted atazanavir and trying to sustain suppression using darunavir without nucleosides. Success rates differed among these strategies. -
Perinatal and Neonatal Antiretroviral Use — Updated Guidelines
- May 4, 2009
- HIV/AIDS
The guidelines include new background information but no new clinical recommendations.- Reviewing:
- Perinatal HIV Guidelines Working Group., 2009 Apr 29;:
-
Perinatal and Neonatal Antiretroviral Use — Updated Guidelines
- July 21, 2008
- ACC Editors
- HIV/AIDS
The guidelines include new tables detailing appropriate dosing in HIV-infected pregnant women and in infants.- Reviewing:
- Perinatal HIV Guidelines Working Group., 2008 Jul 8;:
-
Revised Guidelines for Antiretroviral Use in Pregnant Women
- January 14, 2008
- Judith Feinberg, MD
- HIV/AIDS
The guidelines have been reorganized to better reflect issues in clinical practice.- Reviewing:
- Perinatal HIV Guidelines Working Group., 2007 Nov 2;:
-
Antiretroviral Therapy and Cardiovascular Disease Free
- April 25, 2007
- Paul E. Sax, MD
- HIV/AIDS
Long-term treatment with PI- but not NNRTI-based therapy slightly, but significantly, increased the risk for myocardial infarction.- Reviewing:
- The DAD Study Group., N Engl J Med 2007 Apr 26; 356:1723-35. Stein JH., N Engl J Med 2007 Apr 26; 356:1773-5. Hughes MD and Williams PL., N Engl J Med 2007 Apr 26; 356:1705-7.
-
Updated Antiretroviral Treatment Guidelines from DHHS and EACS Free
- December 10, 2007
- Carlos del Rio, MD
- HIV/AIDS
The latest guidelines include new recommendations on resistance testing, earlier initiation of therapy, and use of HLA B*5701 testing in patients considering abacavir. -
Raltegravir, a New HIV Integrase Inhibitor Free
- October 22, 2007
- Rajesh T. Gandhi, MD
- HIV/AIDS
Because raltegravir inhibits a novel viral target, even HIV that is resistant to other antiretroviral-medication classes is sensitive to this drug. -
Risks for Increased Resistance in Patients on Partially Suppressive Antiretroviral Therapy
- November 20, 2006
- Camilla S. Graham, MD, MPH
- HIV/AIDS
Treatment-experienced patients with at least one existing resistance mutation while on a stable, partially suppressive regimen had a 44% estimated risk for developing a new mutation within 1 year.- Reviewing:
- Hatano H et al., Clin Infect Dis 2006 Nov 15; 43:1329-36.
-
New Antiretroviral Drugs, Part II: NRTIs, NNRTIs, and Beyond
- June 1, 1999
- Robert L. Murphy, MD
- HIV/AIDS
Many of the antiretroviral drugs in development offer significant advantages over existing therapies. Treatment in the next millennium promises to be better in many respects: . . . -
New Antiretroviral Drugs, Part I: PIs
- May 1, 1999
- Robert L. Murphy, MD
- HIV/AIDS
This is the first installment of a two-part article on new antiretroviral drugs in development. This article provides details on new protease inhibitors (PIs). The . . . -
Higher Mortality in Rural Patients Despite Comparable Access to Expert Care
- June 25, 2007
- John J.W. Fangman, MD
- HIV/AIDS
Despite having comparable CD4-cell counts at presentation and more commonly receiving ART, patients residing in rural New England had a higher mortality rate than did those living in urban areas.- Reviewing:
- Lahey T et al., AIDS Res Hum Retroviruses 2007 May; 23:693-8.
Sort by:
Items 1 to 20 of 341 results - Relevance
- Date
